General
Oxford-AstraZeneca vaccine shows promise in elderly, trial results by Christmas
Oxford University and AstraZeneca’s potential COVID-19 vaccine produced a strong immune response in older adults, newly published data has showed, with researchers expecting to release late-stage trial results by Christmas.
Key points:
- Late stage Oxford-AstraZeneca trials have shown it develops antibody and T-cell responses in elderly patients
- Rival drugmakers Pfizer-BioNTech and Moderna have recently pushed ahead in the race for a COVID vaccine
- Researchers report no serious side effects from the Oxford-AstraZeneca vaccine
The data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70, who are at higher risk of serious illness and death from COVID-19, could build robust…
Continue Reading
-
Business20 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News16 hours agoWilliam Robinson dies aged 89
-
Business20 hours agoWhat to do with these 3 ASX 200 retail shares after strong price runs: experts
-
General16 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase